178
Participants
Start Date
September 13, 2013
Primary Completion Date
September 9, 2014
Study Completion Date
March 3, 2015
GS-4774
Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
OAV Regimen
Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
Auckland Clinical Studies, Grafton
North Shore LIJ Health System, Manhasset
Medical Pro-care, Flushing
Digestive Disease Associates, PA, Baltimore
Bon Secours St. Mary's Hospital of Richmond, Newport News
University of Miami, Miami
University of Michigan, Ann Arbor
Henry Ford Hospital and Health System, Detroit
Northwestern Memorial Hospital, Chicago
St.Louis University, St Louis
Dumont-UCLA Liver Transplant Center, Los Angeles
Huntington Medical Research Institutes, Pasadena
Kaiser Permanente, San Diego
Kaiser Permanente, San Francisco
Silicon Valley Research Institute, San Jose
Kaiser Permanente, Sacramento
Tufts Medical Center, Boston
Lead Sponsor
Gilead Sciences
INDUSTRY